In-vitro mercaptopyruvate sulfurtransferase species comparison in humans and common laboratory animals.

Bryant M Moeller, Daune L Crankshaw, Jacquie Briggs, Herbert T Nagasawa, Steven E Patterson

Abstract read

In one paragraph

Article in Toxicology letters, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Bryant M MoellerDepartment of Pharmacology, University of Minnesota, 312 Church St SE, Minneapolis, MN 55455, United States; Center for Drug Design, University of Minnesota, 516 Delaware St SE, Minneapolis, MN 55455, United States.

Daune L CrankshawCenter for Drug Design, University of Minnesota, 516 Delaware St SE, Minneapolis, MN 55455, United States.

Jacquie BriggsCenter for Drug Design, University of Minnesota, 516 Delaware St SE, Minneapolis, MN 55455, United States.

Herbert T NagasawaCenter for Drug Design, University of Minnesota, 516 Delaware St SE, Minneapolis, MN 55455, United States.

Steven E PattersonCenter for Drug Design, University of Minnesota, 516 Delaware St SE, Minneapolis, MN 55455, United States. Electronic address: patte219@umn.edu.

Funding

Countermeasures Against Chemical Threats: Countermeasures Against CyanideU01NS058087 · NINDS · UNIVERSITY OF MINNESOTA · PI PATTERSON, STEVEN E · 2006 to 2014

$5.6M

NINDS NIH HHS U01 NS058087

6 · The paper itself

Abstract

Cyanide is a metabolic poison that inhibits cytochrome c oxidase. Its broad applications in manufacturing and history as an agent of warfare/terror highlight the limitations in approved cyanide antidotes for mass casualties. Sulfanegen, a pre-clinical antidote for cyanide poisoning, exploits an endogenous detoxification pathway and should be amenable to mass-casualty scenarios. Because human studies are unethical, determination of appropriate animal species as models in translational studies for FDA approval under the "Animal Rule" are critical. Here, we compared the specific activities of mercaptopyruvate sulfurtransferase (MST, required for sulfanegen's activity), across common laboratory models of cyanide intoxication, and humans. Human MST activities in erythrocytes (measured as micromole pyruvate/min/10

Indexed as

AnimalsErythrocytesFemaleGene Expression Regulation, EnzymologicHumansHydrolasesKidneyLiverMaleSpecies SpecificitySulfurtransferasescyanide dihydrataseHydrolasesSulfurtransferasesCyanide antidoteMercaptopyruvate sulfurtransferaseSpecies comparisonSulfanegen

Identifiers

PMID28412453

DOI10.1016/j.toxlet.2017.04.005

PMCPMC5505176

What OpenQuestion holds

Textmetadata

LicenceTDM

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.